Browse > Article

Status of High Risk Group Fabry Disease Screening in Korea by Measuring Globotriacocylceramide in Body Fluid using Electrospray-MS/MS  

Yoon, Hye-Ran (Dept. of Biomedical & Analytical Chemistry, College of Pharmacy, Duksung Women's University)
Publication Information
YAKHAK HOEJI / v.55, no.1, 2011 , pp. 56-63 More about this Journal
Abstract
Fabry disease (FD) is an X-linked inborn error of glycoshpingolipid metabolism resulting from mutation in the enzyme ${\alpha}$-galactosidase A gene. The disease is an X-linked lipid storage disorder and the lack of ${\alpha}$-Gal A causes an intracellular accumulation of glycosphingolipids, mainly globotriaosylceramide (Gb-3). Measurement of Gb-3 in plasma has clinical importance for monitoring after enzyme replacement therapy for confirmed FD patients. Using electrospray ionization MS/MS we had developed, a simple, rapid, and highly sensitive analytical method for Gb-3 in plasma was used for the purpose of screening FD among high risk groups in Korean population. To date, no comprehensive results for FD screening have been performed and reported in Korea. We screened 1,100 outpatients from 13 hospitals (including clinics) to assess the incidence of FD among patients in high risk groups. For patients with borderline level amount of Gb-3, we repeated Gb-3 or performing complementary or confirmative assay with ${\alpha}$-Gal A activity and DNA mutaion analysis for confirmation diagnosis. Of 1,100 we diagnosed 3 FD with 2 classical type and 1 carrier (0.27%).
Keywords
fabry disease screening; globotriaosylceramide; electrospary-MS/MS; inherited metabolic disorder; incidence;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Kitagawa, T., Ishige, N., Suzuki, K., Owada, M., Ohashi, T., Kobayashi, M., Eto, Y., Tanaka, A., Mills, K., Winchester, B. and Keutzer, J. : Non-invasive screening method for Fabry disease by measuring globotriaosylceramide in whole urine samples using tandem mass spectrometry. Mol. Genet. Metab. 85, 196 (2005).   DOI   ScienceOn
2 Rozenfeld, P. A., Tarabuso, A., Ebner, R., Ramallo, G. and Fossati, C. A. : A successful approach for the detection of Fabry patients in Argentina. Clin. Genet. 69, 344 (2006).   DOI   ScienceOn
3 Hasegawa, H., Takano, H., Shindo, S., Takeda, S., Funabashi, N., Nakagawa, K., Toyozaki, T., Kuwabara, Y. and Komuro, I. : Images in cardiovascular medicine. Transition from left ventricular hypertrophy to massive fibrosis in the cardiac variant of Fabry disease. Circulation. 113, e720 (2006).   DOI
4 Liu, H. J., Cao, K. J., Li, C. R., Dai, J., Ma, J. Z., Yong, Y. H. and Sun, W. : Alpha-galactosidase A gene mutation in a Chinese family with Fabry disease mimicking clinical features of hypertrophic cardiomyopathy. Zhonghua Xin Xue Guan Bing Za Zhi. 34, 143 (2006).
5 Lindsay, A. C., Behar, J. M. and McEwan, J. : Images in cardiology. Fabry's disease, an X-linked recessive condition, can have isolated cardiac manifestations in heterozygote females. Heart. 92, 685 (2006).   DOI   ScienceOn
6 Hagege, A. A., Caudron, E., Damy, T., Roudaut, R., Millaire, A., Etchecopar-Chevreuil, C., Tran, T. C., Jabbour, F., Boucly, C., Prognon, P., Charron, P. and Germain, D. P. : Screening patients with hypertrophic cardiomyopathy for Fabry disease using a filter-paper test : the FOCUS study. Heart. 97, 131 (2011).   DOI   ScienceOn
7 Yoon, H.-R., Cho, K., Kang, S., Kwon, Y. J., Jeong, C. S. and Lee, Y. S. : Method development for the profiling analysis of urine globotriaosylceramide (Gb-3) for the screening of Fabry disease by tandem mass spectrometry. Yakhak Hoej 51, 96 (2007).
8 Choi, J. H., Cho, Y. M., Suh, K. S., Yoon, H. R., Kim, G. H., Kim, S. S., Ko, J. M., Lee, J. H., Park, Y. S. and Yoo, H. W. : Short-term efficacy of enzyme replacement therapy in Korean patients with Fabry disease. J. Korean Med. Sci. 23, 243 (2008).   DOI   ScienceOn
9 Hoffmann, B., Georg, Koch, H., Schweitzer-Krantz, S., Wendel, U. and Mayatepek, E. : Deficient alpha-galactosidase A activity in plasma but no Fabry disease-a pitfall in diagnosis. Clin. Chem. Lab. Med. 43, 1276 (2005).
10 Zeidner, K. M., Desnick, R. J. and Ioannou, Y. A. : Quantitative determination of globotriaosylceramide by immunodetection of glycolipid-bound recombinant verotoxin B subunit. Anal. Biochem. 267, 104 (1999).   DOI   ScienceOn
11 Ohshima, T., Murray, G. J., Swaim, W. D., Longenecker, G., Quirk, J. M., Cardarelli, C. O., Sugimoto, Y., Pastan, I., Gottesman, M. M., Brady, R. O. and Kulkarni, A. B. : alpha- Galactosidase A deficient mice: a model of Fabry disease. Proc. Natl. Acad. Sci. USA 94, 2540 (1997).   DOI   ScienceOn
12 Hoffmann, B. and Mayatepek, E. : Neurological manifestations in lysosomal storage disorders - from pathology to first therapeutic possibilities. Neuropediatrics 36, 285 (2005).   DOI   ScienceOn
13 Ichinose, M., Nakayama, M., Ohashi, T., Utsunomiya, Y., Kobayashi, M. and Eto, Y. : Significance of screening for Fabry disease among male dialysis patients. Clin. Exp. Nephrol. 9, 228 (2005).   DOI   ScienceOn
14 Bierer, G., Kamangar, N., Balfe, D., Wilcox, W. R. and Mosenifar, Z. : Cardiopulmonary exercise testing in fabry disease. Respiration 72, 504 (2005).   DOI   ScienceOn
15 Linthorst, G. E., Hollak, C. E., Korevaar, J. C., Van Manen, J. G., Aerts, J. M. and Boeschoten, E. W. : Alpha-Galactosidase A deficiency in Dutch patients on dialysis: a critical appraisal of screening for Fabry disease. Nephrol. Dial. Transplant. 18, 1581 (2003).   DOI
16 Mills, K., Morris, P., Lee, P., Vellodi, A., Waldek, S., Young, E. and Winchester, B. : Measurement of urinary CDH and CTH by tandem mass spectrometry in patientshemizygous and heterozygous for Fabry disease. J. Inherit. Metab. Dis. 28, 35 (2005).   DOI   ScienceOn
17 Bekri, S., Enica, A., Ghafari, T., Plaza, G., Champenois, I., Choukroun, G., Unwin, R. and Jaeger, P. : Fabry disease in patients with end-stage renal failure: the potential benefits of screening. Nephron. Clin. Pract. 101, c33 (2005).   DOI   ScienceOn
18 Ichinose, M., Nakayama, M., Ohashi, T., Utsunomiya, Y., Kobayashi, M. and Eto, Y. : Significance of screening for Fabry disease among male dialysis patients. Clin. Exp. Nephrol. 9, 228 (2005).   DOI   ScienceOn
19 Lee, J. K., Kim, G. H., Kim, J. S., Kim, K. K., Lee, M. C. and Yoo, H. W. : Identification of four novel mutations in five unrelated Korean families with Fabry disease. Clin. Genet. 58, 228 (2000).
20 Boscaro, F., Pieraccini, G., la, Marca, G., Bartolucci, G., Luceri, C., Luceri, F. and Oneti, G. : Rapid quantitation of globotriaosylceramide in human plasma and urine: a potential application for monitoring enzyme replacement therapy in Anderson-Fabry disease. Rapid Commun Mass Spectrom. 16, 1507 (2002).   DOI   ScienceOn
21 Mills, K. and Johnson, A. : Winchester Synthesis of novel internal standards for the quantitative determination of plasma ceramide trihexoside in Fabry disease by tandem mass spectrometry. B. FEBS Lett. 515, 171 (2002).   DOI
22 Eng, C. M., Guffon, N., Wilcox, W. R., Germain, D. P., Lee, P., Waldek, S., Caplan, L., Linthorst, G. E. and Desnick, R. J. : International collaborative fabry disease study group. N. Engl. J. Med. 45, 9 (2001).
23 Desnick, R. J., Ioannou, Y. A., Ioannon, C. M., Scriver, C. R., Beaudet, A. L., Sly, W. S., Valle, D., Kinzler, K. E. and Vogelstein, B. : The Metabolic and Molecular Bases of Inherited Disease. MeGraw-Hill, New York 3733-3774 (2001).
24 Nakanishi, T., Funahashi, S., Funai, T., Hashimoto, T. and Shimizu, A. : Chemical diagnosis of Fabry's disease by fluorometric assay and fast atombombardment/mass spectrometry. Ann. Clin. Biochem. 28, 368 (1991).   DOI
25 Caudron, E., Moliere, D., Zhou, J. Y., Prognon, P. and Germain, D. P. : Recent advances of Fabry disease screening for at risk population. Med. Sci. (Paris) 21, 480 (2005).
26 Tanaka, M., Ohashi, T., Kobayashi, M., Eto, Y., Miyamura, N., Nishida, K., Araki, E., Itoh, K., Matsushita, K., Hara, M., Kuwahara, K., Nakano, T. and Yasumoto, N. : Nonoguchi H,Tomita K.Identification of Fabry's disease by the screening of alpha-galactosidase A activity in male and female hemodialysis patients. Clin. Nephrol. 64, 281 (2005).   DOI
27 Desnick, R. J. and Brady, R. O. : Fabry disease in childhood. J. Pediatr. 144, S20 (2004).   DOI   ScienceOn
28 Chien, Y. H., Olivova, P., Zhang, X. K., Chiang, S. C., Lee, N. C., Keutzer, J. and Hwu, W. L. : Elevation of urinary globotriaosylceramide (GL3) in infants with Fabry disease. Mol. Genet. Metab. 102, 57 (2011).   DOI   ScienceOn
29 Whitfield, P. D., Calvin, J., Hogg, S., O'Driscoll, E., Halsall, D., Burling, K., Maguire, G., Wright, N., Cox, T. M., Meikle, P. J. and Deegan, P. B. : Monitoring enzyme replacement therapy in Fabry disease-role of urine globotriaosylceramide. J. Inherit. Metab. Dis. 28, 21 (2005).   DOI   ScienceOn
30 Boscaro, F., Pieraccini, G., la, Marca, G., Bartolucci, G., Luceri, C., Luceri, F. and Oneti, G. : Rapid quantitation of globotriaosylceramide in human plasma and urine a potential application for monitoring enzyme replacement therapy in Anderson-Fabry disease. Rapid Commun Mass Spectrom. 16, 1507 (2002).   DOI   ScienceOn
31 Nelson, B. C., Roddy, T., Araghi, S., Wilkens, D., Thomas, J. J., Zhang, K., Sung, C. C. and Richards, S. M. : Globotriaosylceramide isoform profiles in human plasma by liquid chromatography-tandem mass spectrometry. J. Chromatogr. B 5, 805, 127 (2004).